This page contains a Flash digital edition of a book.
| EDITORIAL


and Healthcare products Regulatory Agency (MHRA) ® acted appropriately and followed clinical advice, there is still room for improvement and Ôserious lessons must be learnedÕ . Further to this, the report suggests that regulators on a Europe-wide basis should learn to


A Affiliated partners: Delicious Flickr


Rosalind Hill Managing Editor, PRIME rosalind.hill@informa.com twitter.com/PrimeJournal


work together better to support the earlier detection of problems, share the information they gather, and take appropriate action to protect patients. This is all well and good in theory, but in practice such aims never seem to get off the


that the product we use is safe? What evidence is there to support its efficacy?


ground. Not only are there language barriers and vast differences among the healthcare systems, but there are also great differences in the roles which the regulators play within each country and healthcare specialty. As a result, this has led many professional


How do we know


bodies to call for one Europe-wide regulator to prevent such instances as the PIP scandal from happening again. Another great idea in theory, but I honestly


believe the logistics wonÕt work. So, it is left to us as health professionals to continually strive for the best for our patients, using the evidence base to support the work we do. The safety of the patient must come first.


How do we know that the product is safe? What evidence is there to support its efficacy?


How is the product manufactured? Has it been extensively tested and researched? Are you and your patients satisfied with the results? These are the questions we should ask before beginning any procedure, and with any


product ® whether you have used it for a long time or not. The reputation of the industry relies on us to obtain the correct evidence and know exactly how to use and adapt it to our practice. We should not allow ourselves to become laissez-faire because we have been practicing for many years, but should ensure that our knowledge is up-to-date and of the best possible quality for our daily practice.


T THE MOMENT IT SEEMS THERE ISNÕT A WEEK THAT GOES BY without an update on the PIP scandal, which finally erupted after months of speculation earlier this year. This time the update comes from the UK Department of Health, following health minister Lord HoweÕs report into the scandal. The report concludes that, although the UK regulator ® the Medicines


Twitter


Retweet Facebook MySpace StumbleUpon Digg


You can download the PRIME App for FREE by searching for ÔPrime JournalÕ in the App Store.


FIND US ON TWITTER, FACEBOOK & LINKEDIN Slash Dot


Join PRIMEÕs editorial team for the latest updates in aesthetic and anti-ageing medicine, debates, and interaction with your peers and colleagues, conference information and special offers


Mixx


Follow us @PrimeJournal


s Flickr Reddit TwitterFriendFeed @PrimeJournal Follow us Delicious Skype


Search for Prime Journal


RetweetFacebook YouTube Flickr Technorati


Search for Prime Journal


MySpace LinkedIn prime-journal.com | June 2012 ❚


StumbleU 3


Twitter


Scar Removal





Facial Implants





Industry News Research Round-up Cellulite ❚ ❚





Event Updates


INTERNATIONAL JOURNAL OF AESTHETIC AND ANTI-AGEING MEDICINE June 2012


Volume 2 ❙ Issue 4


NEURODEGENERATIVE DISEASES EXPLAINED


HORMONE THERAPY


BODY SHAPING WTH RADIOFREQUENCY


HYPERHIDROSIS TREATMENT METHODS


MEN Facial aesthetics for


June 2012 ❙ Volume 2


❙ Issue 4


INTERNATIONAL JOURNAL OF AESTHETIC AND ANTI-AGEING MEDICINE


prime-journal.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84